DE69332911T2 - Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus - Google Patents

Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus

Info

Publication number
DE69332911T2
DE69332911T2 DE69332911T DE69332911T DE69332911T2 DE 69332911 T2 DE69332911 T2 DE 69332911T2 DE 69332911 T DE69332911 T DE 69332911T DE 69332911 T DE69332911 T DE 69332911T DE 69332911 T2 DE69332911 T2 DE 69332911T2
Authority
DE
Germany
Prior art keywords
humanized antibody
antibody against
immunodeficiency virus
human immunodeficiency
against human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332911T
Other languages
English (en)
Other versions
DE69332911D1 (de
Inventor
William Harris
Joseph Carr
Lesley Armour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRD Pharmaceuticals Inc
Original Assignee
Nissin Shokuhin Kk Osaka
Nissin Food Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissin Shokuhin Kk Osaka, Nissin Food Products Co Ltd filed Critical Nissin Shokuhin Kk Osaka
Publication of DE69332911D1 publication Critical patent/DE69332911D1/de
Application granted granted Critical
Publication of DE69332911T2 publication Critical patent/DE69332911T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69332911T 1993-08-24 1993-08-24 Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus Expired - Fee Related DE69332911T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/001798 WO1995006119A1 (en) 1993-08-24 1993-08-24 Recombinant humanized anti-human immunodeficiency virus antibody

Publications (2)

Publication Number Publication Date
DE69332911D1 DE69332911D1 (de) 2003-05-28
DE69332911T2 true DE69332911T2 (de) 2003-12-18

Family

ID=10729537

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332911T Expired - Fee Related DE69332911T2 (de) 1993-08-24 1993-08-24 Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus

Country Status (9)

Country Link
US (1) US5607847A (de)
EP (1) EP0714439B1 (de)
JP (1) JP3741221B2 (de)
KR (1) KR100304333B1 (de)
AT (1) ATE238420T1 (de)
AU (1) AU685397B2 (de)
CA (1) CA2170034C (de)
DE (1) DE69332911T2 (de)
WO (1) WO1995006119A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332911T2 (de) * 1993-08-24 2003-12-18 Nissin Food Products Ltd Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
WO1999013332A1 (fr) * 1997-09-05 1999-03-18 Matsushita Electric Industrial Co., Ltd. Procede de polarisation de fluorescence
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU2002254382B2 (en) 2001-03-22 2007-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant and nonglycosylated cyanovirins
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP2025762A3 (de) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex-Trackingassay
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
WO1991019797A1 (en) * 1990-06-15 1991-12-26 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
CA2094611C (en) * 1991-08-22 2000-07-25 Tsuneya Ohno Hiv immunotherapeutics
WO1993008216A1 (en) * 1991-10-15 1993-04-29 New York University Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv
DE69330280T2 (de) * 1992-08-24 2001-12-06 Nissin Food Products Ltd Immuntherapeutika gegen hiv
DE69332911T2 (de) * 1993-08-24 2003-12-18 Nissin Food Products Ltd Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus

Also Published As

Publication number Publication date
CA2170034A1 (en) 1995-03-02
WO1995006119A1 (en) 1995-03-02
AU685397B2 (en) 1998-01-22
DE69332911D1 (de) 2003-05-28
US5607847A (en) 1997-03-04
CA2170034C (en) 2005-03-15
JPH09501838A (ja) 1997-02-25
EP0714439A1 (de) 1996-06-05
EP0714439B1 (de) 2003-04-23
JP3741221B2 (ja) 2006-02-01
ATE238420T1 (de) 2003-05-15
KR100304333B1 (ko) 2001-11-30
AU4968793A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
DE69332911T2 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
DE3853779D1 (de) Hiv-1 neutralisierende monoklonale antikörper.
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
Pietzsch et al. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity
ES2067866T3 (es) Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.
CA2124126A1 (en) Monoclonal antibodies and fv specific for cd2 antigen
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
KR930702509A (ko) 사람 면역결핍 바이러스(hiv)면역치료제
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
ATE335835T1 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
EP0470184A4 (en) Antibodies specific for cd4-binding domain of hiv
RU93005284A (ru) Моноклональные антитела линии клеток, фармацевтические композиции, способы лечения, фрагмент антитела
Alsmadi et al. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
DE60215676D1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
Braibant et al. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups
Pal et al. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A
ATE201698T1 (de) Immuntherapeutika gegen hiv
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
PT1368478E (pt) Polipeptido indutor de anticorpos neutralizantes de vih
KR920000333A (ko) HIV gp120 모노클로날 항체
CA2046016A1 (en) Hiv monoclonal antibody
ES2073287T3 (es) Metodo para el diagnostico in vitro de infecciones con virus hiv-1.
ATE137801T1 (de) Gegen hiv 1 gp48 spezifische antikörper
Ramirez Valdez Identification, isolation and characterization of monoclonal antibodies against HIV-1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SRD PHARMACEUTICALS,INC., WESTPORT, CONN., US

8339 Ceased/non-payment of the annual fee